Your browser doesn't support javascript.
loading
Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial.
Lacour, J-P; Paul, C; Jazayeri, S; Papanastasiou, P; Xu, C; Nyirady, J; Fox, T; Papavassilis, C.
  • Lacour JP; Department of Dermatology, University Hospital of Nice, Nice, France.
  • Paul C; Department of Dermatology, Paul Sabatier University, Toulouse, France.
  • Jazayeri S; Alliance Dermatology and MOHS Center, Phoenix, AZ, USA.
  • Papanastasiou P; Novartis Pharma AG, Basel, Switzerland.
  • Xu C; Stanford University, Stanford, CA, USA.
  • Nyirady J; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Fox T; Novartis Pharma AG, Basel, Switzerland.
  • Papavassilis C; Novartis Pharma AG, Basel, Switzerland.
J Eur Acad Dermatol Venereol ; 31(5): 847-856, 2017 May.
Article en En | MEDLINE | ID: mdl-28111801
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Año: 2017 Tipo del documento: Article